Trastuzumab was added to Principles of Systemic Therapy in the NCCN Guidelines for Esophageal Cancer and for Gastric Cancer as an option when used in combination with systemic chemotherapy for the treatment of patients with advanced esophageal cancer, gastric cancer, or GE junction adenocarcinoma that is HER-2-positive as determined by a standardized method.
Several updates were made to the NCCN Guidelines for Colon Cancer and for Rectal Cancer based on BRAF gene status. Updates include a new section for BRAF testing added to the Principles of Pathologic Review. For patients with metastatic disease, consideration of tumor BRAF gene status was added to the workup recommendations as an option if KRAS is nonmutated. A new footnote was added stating that "Patients with a known V600E BRAF mutation appear to be unlikely to benefit from anti-EGFR monoclonal antibodies."